Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | Ovarian Cancer | Research

Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes

Authors: Halema Al-Farsi, Iman Al-Azwani, Joel A. Malek, Lotfi Chouchane, Arash Rafii, Najeeb M. Halabi

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

Mutated and non-mutated genes interact to drive cancer growth and metastasis. While research has focused on understanding the impact of mutated genes on cancer biology, understanding non-mutated genes that are essential to tumor development could lead to new therapeutic strategies. The recent advent of high-throughput whole genome sequencing being applied to many different samples has made it possible to calculate if genes are significantly non-mutated in a specific cancer patient cohort.

Methods

We carried out random mutagenesis simulations of the human genome approximating the regions sequenced in the publicly available Cancer Growth Atlas Project for ovarian cancer (TCGA-OV). Simulated mutations were compared to the observed mutations in the TCGA-OV cohort and genes with the largest deviations from simulation were identified. Pathway analysis was performed on the non-mutated genes to better understand their biological function. We then compared gene expression, methylation and copy number distributions of non-mutated and mutated genes in cell lines and patient data from the TCGA-OV project. To directly test if non-mutated genes can affect cell proliferation, we carried out proof-of-concept RNAi silencing experiments of a panel of nine selected non-mutated genes in three ovarian cancer cell lines and one primary ovarian epithelial cell line.

Results

We identified a set of genes that were mutated less than expected (non-mutated genes) and mutated more than expected (mutated genes). Pathway analysis revealed that non-mutated genes interact in cancer associated pathways. We found that non-mutated genes are expressed significantly more than mutated genes while also having lower methylation and higher copy number states indicating that they could be functionally important. RNAi silencing of the panel of non-mutated genes resulted in a greater significant reduction of cell viability in the cancer cell lines than in the non-cancer cell line. Finally, as a test case, silencing ANKLE2, a significantly non-mutated gene, affected the morphology, reduced migration, and increased the chemotherapeutic response of SKOV3 cells.

Conclusion

We show that we can identify significantly non-mutated genes in a large ovarian cancer cohort that are well-expressed in patient and cell line data and whose RNAi-induced silencing reduces viability in three ovarian cancer cell lines. Targeting non-mutated genes that are important for tumor growth and metastasis is a promising approach to expand cancer therapeutic options.
Appendix
Available only for authorised users
Literature
1.
2.
Galletti E, Magnani M, Renzulli ML, Botta M. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007;2(7):920–42.PubMedCrossRef
3.
4.
Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.CrossRef
5.
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446(7132):153–8.PubMedPubMedCentralCrossRef
6.
7.
Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56.PubMedPubMedCentralCrossRef
8.
Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Can Res. 1991;51(11):2979–84.
9.
Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol. 2000;16(3):567–76.PubMed
10.
Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Can Res. 1991;51(19):5171–6.
11.
12.
13.
Rafii A, Halabi NM, Malek JA. High-prevalence and broad spectrum of cell adhesion and extracellular matrix gene pathway mutations in epithelial ovarian cancer. J Clin Bioinforma. 2012;2(1):15.PubMedPubMedCentralCrossRef
14.
Guerrouahen BS, Pasquier J, Kaoud NA, Maleki M, Beauchamp MC, Yasmeen A, et al. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer. Mol Cancer Ther. 2014;13(12):3123–36.PubMedCrossRef
15.
Halabi NM, Martinez A, Al-Farsi H, Mery E, Puydenus L, Pujol P, et al. Preferential allele expression analysis identifies shared germline and somatic driver genes in advanced ovarian cancer. PLoS Genet. 2016;12(1):e1005755.PubMedPubMedCentralCrossRef
16.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15–21.PubMedCrossRef
17.
Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923–30.PubMedCrossRef
18.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40.PubMedCrossRef
19.
Hu WH, Pendergast JS, Mo XM, Brambilla R, Bracchi-Ricard V, Li F, et al. NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation. J Biol Chem. 2005;280(32):29233–41.PubMedCrossRef
20.
Grunewald TG, Pasedag SM, Butt E. Cell adhesion and transcriptional activity—defining the role of the novel protooncogene LPP. Transl Oncol. 2009;2(3):107–16.PubMedPubMedCentralCrossRef
21.
Guo B, Sallis RE, Greenall A, Petit MM, Jansen E, Young L, et al. The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3. Mol Cell Biol. 2006;26(12):4529–38.PubMedPubMedCentralCrossRef
22.
Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM. A complex containing LPP and alpha-actinin mediates TGFbeta-induced migration and invasion of ErbB2-expressing breast cancer cells. J Cell Sci. 2013;126(Pt 9):1981–91.PubMed
23.
Zhang B, Zhao H, Li T, Gao X, Gao Q, Tang R, et al. Association study of gene LPP in women with polycystic ovary syndrome. PLoS ONE. 2012;7(10):e46370.PubMedPubMedCentralCrossRef
24.
Qu Z, Yu J, Ruan Q. TGF-beta1-induced LPP expression dependant on Rho kinase during differentiation and migration of bone marrow-derived smooth muscle progenitor cells. J of Huazhong University of Sci and Technol Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban. 2012;32(4):459–65.CrossRef
25.
Petit MM, Meulemans SM, Alen P, Ayoubi TA, Jansen E, Van de Ven WJ. The tumor suppressor Scrib interacts with the zyxin-related protein LPP, which shuttles between cell adhesion sites and the nucleus. BMC Cell Biol. 2005;6(1):1.PubMedPubMedCentralCrossRef
26.
Asencio C, Davidson IF, Santarella-Mellwig R, Ly-Hartig TB, Mall M, Wallenfang MR, et al. Coordination of kinase and phosphatase activities by Lem4 enables nuclear envelope reassembly during mitosis. Cell. 2012;150(1):122–35.PubMedCrossRef
27.
28.
Lang RA, Herman K, Reynolds AB, Hildebrand JD, Plageman TF Jr. p120-catenin-dependent junctional recruitment of Shroom3 is required for apical constriction during lens pit morphogenesis. Development. 2014;141(16):3177–87.PubMedPubMedCentralCrossRef
29.
Plageman TF Jr, Zacharias AL, Gage PJ, Lang RA. Shroom3 and a Pitx2-N-cadherin pathway function cooperatively to generate asymmetric cell shape changes during gut morphogenesis. Dev Biol. 2011;357(1):227–34.PubMedPubMedCentralCrossRef
30.
Chung MI, Nascone-Yoder NM, Grover SA, Drysdale TA, Wallingford JB. Direct activation of Shroom3 transcription by Pitx proteins drives epithelial morphogenesis in the developing gut. Development. 2010;137(8):1339–49.PubMedPubMedCentralCrossRef
31.
Nishimura T, Takeichi M. Shroom3-mediated recruitment of Rho kinases to the apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development. 2008;135(8):1493–502.PubMedCrossRef
32.
Lee C, Scherr HM, Wallingford JB. Shroom family proteins regulate gamma-tubulin distribution and microtubule architecture during epithelial cell shape change. Development. 2007;134(7):1431–41.PubMedCrossRef
33.
Hildebrand JD. Shroom regulates epithelial cell shape via the apical positioning of an actomyosin network. J Cell Sci. 2005;118(Pt 22):5191–203.PubMedCrossRef
34.
Bonkhoff H, Fixemer T, Hunsicker I, Remberger K. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate. 2001;48(4):285–91.PubMedCrossRef
35.
Yu Y, Yang O, Fazli L, Rennie PS, Gleave ME, Dong X. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation. Prostate. 2015;75(10):1043–50.PubMedCrossRef
36.
Avci N, Deligonul A, Tolunay S, Cubukcu E, Fatih Olmez O, Ulas A, et al. Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer. J BUON Official J Balkan Union of Oncol. 2015;20(1):45–9.
37.
De Amicis F, Guido C, Santoro M, Lanzino M, Panza S, Avena P, et al. A novel functional interplay between Progesterone Receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cells. J Cell Mol Med. 2014;18(11):2252–65.PubMedPubMedCentralCrossRef
38.
Lee SY, Kim JW, Jeong MH, An JH, Jang SM, Song KH, et al. Microtubule-associated protein 1B light chain (MAP1B-LC1) negatively regulates the activity of tumor suppressor p53 in neuroblastoma cells. FEBS Lett. 2008;582(19):2826–32.PubMedCrossRef
39.
Sun H, Hu XQ, Emerit MB, Schoenebeck JC, Kimmel CE, Peoples RW, et al. Modulation of 5-HT3 receptor desensitization by the light chain of microtubule-associated protein 1B expressed in HEK 293 cells. J Physiol. 2008;586(3):751–62.PubMedCrossRef
40.
Harrison B, Kraus M, Burch L, Stevens C, Craig A, Gordon-Weeks P, et al. DAPK-1 binding to a linear peptide motif in MAP1B stimulates autophagy and membrane blebbing. J Biol Chem. 2008;283(15):9999–10014.PubMedCrossRef
41.
Montenegro-Venegas C, Tortosa E, Rosso S, Peretti D, Bollati F, Bisbal M, et al. MAP1B regulates axonal development by modulating Rho-GTPase Rac1 activity. Mol Biol Cell. 2010;21(20):3518–28.PubMedPubMedCentralCrossRef
42.
Tortosa E, Galjart N, Avila J, Sayas CL. MAP1B regulates microtubule dynamics by sequestering EB1/3 in the cytosol of developing neuronal cells. EMBO J. 2013;32(9):1293–306.PubMedPubMedCentralCrossRef
43.
Fuhrmann-Stroissnigg H, Noiges R, Descovich L, Fischer I, Albrecht DE, Nothias F, et al. The light chains of microtubule-associated proteins MAP1A and MAP1B interact with alpha1-syntrophin in the central and peripheral nervous system. PLoS ONE. 2012;7(11):e49722.PubMedPubMedCentralCrossRef
44.
Tymanskyj SR, Scales TM, Gordon-Weeks PR. MAP1B enhances microtubule assembly rates and axon extension rates in developing neurons. Mol Cell Neurosci. 2012;49(2):110–9.PubMedCrossRef
45.
46.
Litterman N, Ikeuchi Y, Gallardo G, O’Connell BC, Sowa ME, Gygi SP, et al. An OBSL1-Cul7Fbxw8 ubiquitin ligase signaling mechanism regulates Golgi morphology and dendrite patterning. PLoS Biol. 2011;9(5):e1001060.PubMedPubMedCentralCrossRef
47.
Geisler SB, Robinson D, Hauringa M, Raeker MO, Borisov AB, Westfall MV, et al. Obscurin-like 1, OBSL1, is a novel cytoskeletal protein related to obscurin. Genomics. 2007;89(4):521–31.PubMedCrossRef
48.
Tatin F, Taddei A, Weston A, Fuchs E, Devenport D, Tissir F, et al. Planar cell polarity protein Celsr1 regulates endothelial adherens junctions and directed cell rearrangements during valve morphogenesis. Dev Cell. 2013;26(1):31–44.PubMedPubMedCentralCrossRef
49.
Carreira-Barbosa F, Kajita M, Morel V, Wada H, Okamoto H, Martinez Arias A, et al. Flamingo regulates epiboly and convergence/extension movements through cell cohesive and signalling functions during zebrafish gastrulation. Development. 2009;136(3):383–92.PubMedCrossRef
50.
Li Z, Park HR, Shi Z, Li Z, Pham CD, Du Y, et al. Pro-oncogenic function of HIP-55/Drebrin-like (DBNL) through Ser269/Thr291-phospho-sensor motifs. Oncotarget. 2014;5(10):3197–209.PubMedPubMedCentralCrossRef
51.
Yang C, Li Z, Shi Z, He K, Tian A, Wu J, et al. Regulation of cell survival by the HIP-55 signaling network. Mol BioSyst. 2014;10(6):1393–9.PubMedCrossRef
52.
Han J, Shui JW, Zhang X, Zheng B, Han S, Tan TH. HIP-55 is important for T-cell proliferation, cytokine production, and immune responses. Mol Cell Biol. 2005;25(16):6869–78.PubMedPubMedCentralCrossRef
53.
Liu N, Xing R, Yang C, Tian A, Lv Z, Sun N, et al. HIP-55/DBNL-dependent regulation of adrenergic receptor mediates the ERK1/2 proliferative pathway. Mol BioSyst. 2014;10(7):1932–9.PubMedCrossRef
54.
Kim HG, Kim HT, Leach NT, Lan F, Ullmann R, Silahtaroglu A, et al. Translocations disrupting PHF21A in the Potocki-Shaffer-syndrome region are associated with intellectual disability and craniofacial anomalies. Am J Hum Genet. 2012;91(1):56–72.PubMedPubMedCentralCrossRef
55.
Klajn A, Ferrai C, Stucchi L, Prada I, Podini P, Baba T, et al. The rest repression of the neurosecretory phenotype is negatively modulated by BHC80, a protein of the BRAF/HDAC complex. J Neurosci Official J Society Neurosci. 2009;29(19):6296–307.CrossRef
56.
Iwase S, Januma A, Miyamoto K, Shono N, Honda A, Yanagisawa J, et al. Characterization of BHC80 in BRAF-HDAC complex, involved in neuron-specific gene repression. Biochem Biophys Res Commun. 2004;322(2):601–8.PubMedCrossRef
57.
Kim SY, Yang D, Myeong J, Ha K, Kim SH, Park EJ, et al. Regulation of calcium influx and signaling pathway in cancer cells via TRPV6-Numb1 interaction. Cell Calcium. 2013;53(2):102–11.PubMedCrossRef
58.
Kovacs G, Montalbetti N, Franz MC, Graeter S, Simonin A, Hediger MA. Human TRPV5 and TRPV6: key players in cadmium and zinc toxicity. Cell Calcium. 2013;54(4):276–86.PubMedCrossRef
59.
Tomilin VN, Vasil’eva IO, Marakhova II, Neguliaev IuA, Semenova CB. The functional characteristics oF TRPV5 and TRPV6 channels in normal and transformed human blood lymphocytes. Tsitologiia. 2013;55(5):300–6.PubMed
60.
Vanoevelen J, Janssens A, Huitema LF, Hammond CL, Metz JR, Flik G, et al. Trpv5/6 is vital for epithelial calcium uptake and bone formation. FASEB J Official Publication Federation of American Societies Exp Biol. 2011;25(9):3197–207.CrossRef
61.
62.
Lehen’kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca(2+)/NFAT-dependent pathways. Oncogene. 2007;26(52):7380–5.PubMedCrossRef
63.
Lehen’kyi V, Beck B, Polakowska R, Charveron M, Bordat P, Skryma R, et al. TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes. J Biol Chem. 2007;282(31):22582–91.PubMedCrossRef
64.
Chu LH, Lee E, Bader JS, Popel AS. Angiogenesis interactome and time course microarray data reveal the distinct activation patterns in endothelial cells. PLoS ONE. 2014;9(10):e110871.PubMedPubMedCentralCrossRef
65.
Wang W, Ren F, Wu Q, Jiang D, Li H, Shi H. MicroRNA-497 suppresses angiogenesis by targeting vascular endothelial growth factor A through the PI3K/AKT and MAPK/ERK pathways in ovarian cancer. Oncol Rep. 2014;32(5):2127–33.PubMedCrossRef
66.
Bergantino F, Guariniello S, Raucci R, Colonna G, De Luca A, Normanno N, et al. Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. Biochimica et biophysica acta. 2015;1854:410.PubMedCrossRef
67.
Chen H, Liu D, Yang Z, Sun L, Deng Q, Yang S, et al. Adrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk. Endocr Relat Cancer. 2014;21(5):783–95.PubMedCrossRef
68.
Marinaccio C, Nico B, Maiorano E, Specchia G, Ribatti D. Insights in Hodgkin Lymphoma angiogenesis. Leuk Res. 2014;38(8):857–61.PubMedCrossRef
69.
Andreozzi M, Quagliata L, Gsponer JR, Ruiz C, Vuaroqueaux V, Eppenberger-Castori S, et al. VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. Angiogenesis. 2014;17(3):519–27.PubMedCrossRef
70.
Georgiadou D, Sergentanis TN, Sakellariou S, Filippakis GM, Zagouri F, Vlachodimitropoulos D, et al. VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis. Eur J Surg Oncol J Eur Society of Surg Oncol British Association of Surg Oncol. 2014;40(10):1331–7.
71.
Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, et al. High serum levels of vascular endothelial growth factor-A and transforming growth factor-beta1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy. Ann Surg Oncol. 2014;21(7):2361–8.PubMedCrossRef
72.
Wang R, Tian S, Wang HB, Chu DP, Cao JL, Xia HF, et al. MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett. 2014;588(23):4438–47.PubMedCrossRef
73.
Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol. 2001;106(4):148–56.PubMedCrossRef
74.
Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol. 2001;280(6):C1358–66.PubMedCrossRef
75.
Liang D, Chang JR, Chin AJ, Smith A, Kelly C, Weinberg ES, et al. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. Mech Dev. 2001;108(1–2):29–43.PubMedCrossRef
76.
77.
Nakasaki T, Wada H, Shigemori C, Miki C, Gabazza EC, Nobori T, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol. 2002;69(4):247–54.PubMedCrossRef
78.
Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000–8.PubMedCrossRef
79.
Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Begin LR, et al. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Mol Cell Endocrinol. 2002;189(1–2):169–79.PubMedCrossRef
80.
Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 2002;1(2):193–202.PubMedCrossRef
81.
Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196(11):1497–506.PubMedPubMedCentralCrossRef
82.
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22(3):319–29.PubMedCrossRef
83.
Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Manseau EJ, et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol. 2002;67:227–37.PubMedCrossRef
84.
Takehara M, Ueda M, Yamashita Y, Terai Y, Hung YC, Ueki M. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol. 2004;35(11):1369–75.PubMedCrossRef
85.
Misra C, Restituito S, Ferreira J, Rameau GA, Fu J, Ziff EB. Regulation of synaptic structure and function by palmitoylated AMPA receptor binding protein. Mol Cell Neurosci. 2010;43(4):341–52.PubMedPubMedCentralCrossRef
86.
Mao L, Takamiya K, Thomas G, Lin DT, Huganir RL. GRIP1 and 2 regulate activity-dependent AMPA receptor recycling via exocyst complex interactions. Proc Natl Acad Sci USA. 2010;107(44):19038–43.PubMedPubMedCentralCrossRef
87.
Rondaij MG, Bierings R, van Agtmaal EL, Gijzen KA, Sellink E, Kragt A, et al. Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells. Blood. 2008;112(1):56–63.PubMedCrossRef
88.
Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M, et al. Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol. 2007;27(21):7538–50.PubMedPubMedCentralCrossRef
89.
Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell. 2005;7(3):219–26.PubMedCrossRef
90.
Carmona-Mora P, Canales CP, Cao L, Perez IC, Srivastava AK, Young JI, et al. RAI1 transcription factor activity is impaired in mutants associated with Smith-Magenis Syndrome. PLoS ONE. 2012;7(9):e45155.PubMedPubMedCentralCrossRef
91.
Girirajan S, Elsea SH. Distorted Mendelian transmission as a function of genetic background in Rai1-haploinsufficient mice. Eur J Med Genet. 2009;52(4):224–8.PubMedCrossRef
92.
Walz K, Paylor R, Yan J, Bi W, Lupski JR. Rai1 duplication causes physical and behavioral phenotypes in a mouse model of dup(17)(p11.2p11.2). J Clin Invest. 2006;116(11):3035–41.PubMedPubMedCentralCrossRef
93.
Gubanova E, Issaeva N, Gokturk C, Djureinovic T, Helleday T. SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle. 2013;12(24):3770–80.PubMedPubMedCentralCrossRef
94.
Han LL, Nan HC, Tian T, Guo H, Hu TH, Wang WJ, et al. Expression and significance of the novel tumor-suppressor gene SMG-1 in hepatocellular carcinoma. Oncol Rep. 2014;31(6):2569–78.PubMedCrossRef
95.
Roberts TL, Ho U, Luff J, Lee CS, Apte SH, MacDonald KP, et al. Smg1 haploinsufficiency predisposes to tumor formation and inflammation. Proc Natl Acad Sci USA. 2013;110(4):E285–94.PubMedCrossRef
96.
Hoarau-Vechot J, Touboul C, Halabi N, Blot-Dupin M, Lis R, Abi Khalil C, et al. Akt-activated endothelium promotes ovarian cancer proliferation through notch activation. J Transl Med. 2019;17(1):194.PubMedPubMedCentralCrossRef
97.
Miranda-Goncalves V, Lobo J, Guimaraes-Teixeira C, Barros-Silva D, Guimaraes R, Cantante M, et al. The component of the m(6)A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. J Exp Clin Cancer Res. 2021;40(1):268.PubMedPubMedCentralCrossRef
98.
Xu Y, Chen Y, Yao Y, Xie H, Lu G, Du C, et al. VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification. Cancer Lett. 2021;522:142–54.PubMedCrossRef
99.
Kaufmann T, Kukolj E, Brachner A, Beltzung E, Bruno M, Kostrhon S, et al. SIRT2 regulates nuclear envelope reassembly through ANKLE2 deacetylation. J Cell Sci. 2016;129(24):4607–21.PubMedPubMedCentral
100.
Link N, Chung H, Jolly A, Withers M, Tepe B, Arenkiel BR, et al. Mutations in ANKLE2, a ZIKA virus target, disrupt an asymmetric cell division pathway in Drosophila neuroblasts to cause microcephaly. Dev Cell. 2019;51(6):713-29.e6.PubMedPubMedCentralCrossRef
101.
Ueno NT, Bartholomeusz C, Herrmann JL, Estrov Z, Shao R, Andreeff M, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res Official J Am Association Cancer Res. 2000;6(1):250–9.
102.
Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001;81(3):380–90.PubMedCrossRef
103.
104.
Sudarsanam P, Winston F. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends Genet TIG. 2000;16(8):345–51.PubMedCrossRef
105.
Roberts CW, Orkin SH. The SWI/SNF complex–chromatin and cancer. Nat Rev Cancer. 2004;4(2):133–42.PubMedCrossRef
106.
Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455–64.PubMedCrossRef
107.
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004;30(2):193–204.PubMedCrossRef
Metadata
Title
Discovery of new therapeutic targets in ovarian cancer through identifying significantly non-mutated genes
Authors
Halema Al-Farsi
Iman Al-Azwani
Joel A. Malek
Lotfi Chouchane
Arash Rafii
Najeeb M. Halabi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03440-5

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue

Research

Integrative metagenomic and metabolomic analyses reveal the role of gut microbiota in antibody-mediated renal allograft rejection

Research

Proton magnetic resonance spectroscopy detects cerebral metabolic derangement in a mouse model of brain coenzyme a deficiency

Research

High VSX1 expression promotes the aggressiveness of clear cell renal cell carcinoma by transcriptionally regulating FKBP10

Research

Molecular dissection of a hyper-aggressive CBFB-MYH11/FLT3-ITD–positive acute myeloid leukemia

Research

GDF11 alleviates neointimal hyperplasia in a rat model of artery injury by regulating endothelial NLRP3 inflammasome activation and rapid re-endothelialization

Research

The association between bilirubin and hypertension among a Chinese ageing cohort: a prospective follow-up study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits